{"id":37592,"date":"2025-07-18T22:20:44","date_gmt":"2025-07-18T14:20:44","guid":{"rendered":"https:\/\/flcube.com\/?p=37592"},"modified":"2025-07-18T22:20:45","modified_gmt":"2025-07-18T14:20:45","slug":"gsks-blenrep-fails-to-win-fda-advisory-committee-support-for-relapsed-multiple-myeloma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=37592","title":{"rendered":"GSK&#8217;s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma"},"content":{"rendered":"\n<p>UK-based GlaxoSmithKline (GSK; <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>)\u00a0 announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit\/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations. The evaluation was for use in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The FDA will take the committee&#8217;s recommendation into account as it finalizes its review ahead of the July 23, 2025 PDUFA date. GSK maintains confidence in Blenrep&#8217;s benefit\/risk profile and will continue working closely with the FDA during the review process.<\/p>\n\n\n\n<p><strong>Blenrep Overview<\/strong><br>Blenrep is an antibody-drug conjugate (ADC) composed of a humanized BCMA monoclonal antibody linked to the cytotoxic agent auristatin F via a non-cleavable linker. Blenrep combinations are approved for relapsed or refractory multiple myeloma in the UK, Japan, and other markets, including Switzerland. Applications are under review in major markets such as the European Union and China, supported by the results of the DREAMM-7 trial, which received Breakthrough Therapy Designation and priority review.<\/p>\n\n\n\n<p><strong>Clinical Trial Results<\/strong><br>Both the DREAMM-7 and DREAMM-8 Phase 3 trials achieved their primary endpoint of progression-free survival (PFS). However, DREAMM-7 met the key secondary endpoint of overall survival (OS), while DREAMM-8 did not. Safety data indicated a relatively high incidence of grade 3-4 treatment-emergent adverse events (TEAEs), leading to dose adjustments or discontinuations in a number of patients. Ocular toxicity was also reported, which is a unique toxicity not observed with current multiple myeloma treatments.<\/p>\n\n\n\n<p><strong>ODAC Concerns<\/strong><br>According to ODAC materials, the main efficacy concern was the lack of statistically significant improvement in OS in DREAMM-8 and limited enrollment diversity. Additionally, the committee highlighted ocular toxicity as a unique safety issue. The ODAC experts ultimately voted against approval by a margin of 5:3.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0 announced that the US Food and Drug Administration (FDA) Oncologic&#8230;<\/p>\n","protected":false},"author":1,"featured_media":37593,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,278,184,914],"class_list":["post-37592","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK&#039;s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0 announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit\/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations. The evaluation was for use in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The FDA will take the committee&#039;s recommendation into account as it finalizes its review ahead of the July 23, 2025 PDUFA date. GSK maintains confidence in Blenrep&#039;s benefit\/risk profile and will continue working closely with the FDA during the review process.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=37592\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK&#039;s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma\" \/>\n<meta property=\"og:description\" content=\"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0 announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit\/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations. The evaluation was for use in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The FDA will take the committee&#039;s recommendation into account as it finalizes its review ahead of the July 23, 2025 PDUFA date. GSK maintains confidence in Blenrep&#039;s benefit\/risk profile and will continue working closely with the FDA during the review process.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=37592\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-18T14:20:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-18T14:20:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37592#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37592\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK&#8217;s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma\",\"datePublished\":\"2025-07-18T14:20:44+00:00\",\"dateModified\":\"2025-07-18T14:20:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37592\"},\"wordCount\":315,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37592#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1803-1.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37592#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37592\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=37592\",\"name\":\"GSK's Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37592#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37592#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1803-1.webp\",\"datePublished\":\"2025-07-18T14:20:44+00:00\",\"dateModified\":\"2025-07-18T14:20:45+00:00\",\"description\":\"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0 announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit\\\/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations. The evaluation was for use in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The FDA will take the committee's recommendation into account as it finalizes its review ahead of the July 23, 2025 PDUFA date. GSK maintains confidence in Blenrep's benefit\\\/risk profile and will continue working closely with the FDA during the review process.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37592#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=37592\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37592#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1803-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/1803-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK's Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=37592#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK&#8217;s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK's Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","description":"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0 announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit\/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations. The evaluation was for use in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The FDA will take the committee's recommendation into account as it finalizes its review ahead of the July 23, 2025 PDUFA date. GSK maintains confidence in Blenrep's benefit\/risk profile and will continue working closely with the FDA during the review process.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=37592","og_locale":"en_US","og_type":"article","og_title":"GSK's Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma","og_description":"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0 announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit\/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations. The evaluation was for use in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The FDA will take the committee's recommendation into account as it finalizes its review ahead of the July 23, 2025 PDUFA date. GSK maintains confidence in Blenrep's benefit\/risk profile and will continue working closely with the FDA during the review process.","og_url":"https:\/\/flcube.com\/?p=37592","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-18T14:20:44+00:00","article_modified_time":"2025-07-18T14:20:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=37592#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=37592"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK&#8217;s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma","datePublished":"2025-07-18T14:20:44+00:00","dateModified":"2025-07-18T14:20:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=37592"},"wordCount":315,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=37592#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803-1.webp","keywords":["ADC \/ XDC","GlaxoSmithKline","GSK","NYSE: GSK"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=37592#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=37592","url":"https:\/\/flcube.com\/?p=37592","name":"GSK's Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=37592#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=37592#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803-1.webp","datePublished":"2025-07-18T14:20:44+00:00","dateModified":"2025-07-18T14:20:45+00:00","description":"UK-based GlaxoSmithKline (GSK; NYSE: GSK)\u00a0 announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted against the overall benefit\/risk profile at the proposed dosage of Blenrep (belantamab mafodotin-blmf) combinations. The evaluation was for use in adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. The FDA will take the committee's recommendation into account as it finalizes its review ahead of the July 23, 2025 PDUFA date. GSK maintains confidence in Blenrep's benefit\/risk profile and will continue working closely with the FDA during the review process.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=37592#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=37592"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=37592#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803-1.webp","width":1080,"height":608,"caption":"GSK's Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=37592#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK&#8217;s Blenrep Fails to Win FDA Advisory Committee Support for Relapsed Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/1803-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37592"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37592\/revisions"}],"predecessor-version":[{"id":37594,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/37592\/revisions\/37594"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/37593"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}